menu
    • menu
    [{"orgOrder":0,"company":"Xentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"XTMAB-16","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xentria \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xentria \/ Not Applicable"},{"orgOrder":0,"company":"Xentria","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"XTMAB-16","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Xentria","amount2":0.68000000000000005,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.68000000000000005,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Xentria \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Xentria","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"XTMAB-16","moa":"","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Xentria","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xentria \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Xentria \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Xentria

    Menu

    Xentria

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xentria’s XTMAB-16 Receives Orphan Drug Designation From European Medicines Agency as First Patient is Enrol...

                            Details : XTMAB-16, an anti-TNFα monoclonal antibody which is being tested in a Phase 1b/2a clinical trial for its ability to potentially help patients with pulmonary sarcoidosis, a chronic, multisystem inflammatory disorder.

                            Brand Name : XTMAB-16

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 15, 2023

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Meitheal Pharmaceuticals

                            Deal Size : $680.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America

                            Details : Under the agreement, Meitheal gains exclusive rights to commercialize XTMAB-16, a monoclonal antibody which aims to treat people with sarcoidosis, in North America and Xentria remains responsible for clinical development and retains the marketing rights ...

                            Brand Name : XTMAB-16

                            Molecule Type : Large molecule

                            Upfront Cash : $45.0 million

                            June 27, 2023

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Meitheal Pharmaceuticals

                            Deal Size : $680.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Xentria

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Xentria to Present Initial Findings from Preclinical Study of XTMAB-16 at ATS 2022 International Conference

                            Details : XTMAB16, an Investigational new drug candidate, is a chimeric human-murine IgG1 anti-TNF monoclonal antibody being developed as a novel biologic product for treatment of sarcoidosis also, suppress the physiologic response to tumor necrosis factor.

                            Brand Name : XTMAB-16

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : XTMAB-16

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth